| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6247071 | Transplantation Proceedings | 2016 | 5 Pages |
â¢The study has demonstrated for the first time that erythropoietin receptor activation protects the kidney from ischemia/reperfusion injury by reducing apoptosis, an effect associated with activation of the ERK/p53 signal pathway.
BackgroundApoptosis plays an important role in renal ischemia/reperfusion (IR) injury. Evidence has shown that erythropoietin (EPO) has an antiapoptotic effect. Therefore, this study aimed to explore the effect and potential mechanism of EPO in renal IR injury.MethodsKidney IR injury in rats was established by clamping the left renal artery for 30 minutes followed by 24 hours of reperfusion, along with contralateral nephrectomy. Renal function, renal histology, and expression of EPOR, p-EPOR, ERK, p-ERK, p-p53, p53, Bcl-2, Bcl-xl, Bad, and Bax were examined.ResultsPretreatment with EPO significantly reduced renal dysfunction, pathologic change, and expression of Bad and Bax. Furthermore, EPO treatment enhanced the expression of p-ERK, p-p53, Bcl-2, and Bcl-xl with no influence on the expression of EPOR, ERK, and p53.ConclusionsThese findings demonstrated that EPO pretreatment can attenuate renal IR injury by inhibiting apoptosis by promoting activation of the ERK/p53 signaling.
